Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

1(33.3%)

Early Phase 1

1(33.3%)

Phase 3

1(33.3%)

3Total

N/A(1)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06339710Phase 3Withdrawn

Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients

Role: lead

NCT02371395Completed

Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil

Role: collaborator

NCT01863576Early Phase 1Completed

Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy

Role: lead

NCT01566617Not ApplicableUnknown

Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease

Role: lead

All 4 trials loaded